de novo
Recently Published Documents


(FIVE YEARS 13370)



Oral Oncology ◽  
2022 ◽  
Vol 125 ◽  
pp. 105711
Gerardo Gilligan ◽  
Eduardo Piemonte ◽  
Jerónimo Lazos ◽  
René Panico

2022 ◽  
Vol 61 ◽  
pp. 100910
Binbin Shan ◽  
Yan Liu ◽  
Changping Yang ◽  
Liangming Wang ◽  
Yuan Li ◽  

2022 ◽  
Vol 72 ◽  
pp. 135-144
Mingyang Wang ◽  
Zhe Wang ◽  
Huiyong Sun ◽  
Jike Wang ◽  
Chao Shen ◽  

2022 ◽  
Vol 176 ◽  
pp. 114353
Pooja Thapa ◽  
Bhuvnesh Sareen ◽  
Mohit Kumar Swarnkar ◽  
Anil Sood ◽  
Amita Bhattacharya

2022 ◽  
Vol 12 (1) ◽  
pp. 15-20
Prakash I Darji ◽  
Himanshu A Patel ◽  
Bhavya P Darji ◽  
Ajay Sharma ◽  
Ahmed Halawa

2022 ◽  
Vol 29 (1) ◽  
pp. 383-391
Marie-France Savard ◽  
Elizabeth N. Kornaga ◽  
Adriana Matutino Kahn ◽  
Sasha Lupichuk

Metastatic breast cancer (MBC) patient outcomes may vary according to distinct health care payers and different countries. We compared 291 Alberta (AB), Canada and 9429 US patients < 65 with de novo MBC diagnosed from 2010 through 2014. Data were extracted from the provincial Breast Data Mart and from the National Cancer Institute’s SEER program. US patients were divided by insurance status (US privately insured, US Medicaid or US uninsured). Kaplan-Meier and log-rank analyses were used to assess differences in OS and hazard ratios (HR) were estimated using Cox models. Multivariate models were adjusted for age, surgical status, and biomarker profile. No difference in OS was noted between AB and US patients (HR = 0.92 (0.77–1.10), p = 0.365). Median OS was not reached for the US privately insured and AB groups, and was 11 months and 8 months for the US Medicaid and US uninsured groups, respectively. The 3-year OS rates were comparable between US privately insured and AB groups (53.28% (51.95–54.59) and 55.54% (49.49–61.16), respectively). Both groups had improved survival (p < 0.001) relative to the US Medicaid and US uninsured groups [39.32% (37.25–41.37) and 40.53% (36.20–44.81)]. Our study suggests that a universal health care system is not inferior to a private insurance-based model for de novo MBC.

2022 ◽  
Richard W Davis ◽  
Charlotte Muse ◽  
Heather Eggleston ◽  
Micaila Hill ◽  
Peter Panizzi

Streptococcus pyogenes (S. pyogenes) can thrive in its host during an infection, and, as a result, it must be able to respond to external stimuli and available carbon sources. The pre-clinical use of engineered pathogens capable of constitutive light production may provide real-time information on microbial-specific metabolic processes. Here we mapped the central metabolism of a luxABCDE-modified S. pyogenes Xen20 (Strep. Xen20) to its de novo synthesis of luciferase substrates as assessed by the rate of light production in response to different environmental triggers. Previous characterization predicted that the lux operon was under the myo-inositol iolE promotor. Here we show that supplementation with myo-inositol generated increased Xen20 luminescence. Surprisingly, when supplemented with infection-relevant carbon sources, such as glucose or glycine, light production was diminished. This was presumably due to the scavenging of pyruvate by L-lactate dehydrogenase (LDH). Inhibition of LDH by its inhibitor, oxamate, partially restored luminescent signal in the presence of glucose, presumably by allowing the resulting pyruvate to proceed to acetyl-coenzyme A (CoA). This phenomenon appeared specific to the lactic acid bacterial metabolism as glucose or glycine did not reduce signal in an analogous luxABCDE-modified Gram-positive pathogen, Staph. Xen29. The Strep. Xen20 cells produced light in a concentration-dependent manner, inversely related to the amount of glucose present. Taken together, our measures of microbial response could provide new information regarding the responsiveness of S. pyogenes metabolism to acute changes in its local environments and cellular health.

Sign in / Sign up

Export Citation Format

Share Document